SARS‐CoV‐2 booster effect and waning immunity in hemodialysis patients: A cohort study

Goggins, Eibhlin; Sharma, Binu; Jennie, Z.; Gautam, Jitendra; Bowman, Brendan

doi:10.1002/hsr2.1040

Cited by 1 publication

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We recently reported the initial results of antibody levels in these patients up to 11 weeks after boosting. 23 Interestingly, immediately following this, we observed a spike in antibody levels in a large newly nucleocapsid positive patients had a documented record of infection. This has multiple important implications.…”

Section: Goldblatt Et Al Reported the Mean Protective Threshold Again...mentioning

confidence: 73%

“…6 A subset of these patients received a third dose of BNT162b2 and their short-term antibody response was reported. 23 Here, we complete the three-part series to fully characterize the natural history of antibody levels in hemodialysis patients following mRNA-based vaccine boosters. Specifically, we provide an additional 7 months of data supplementing our earlier descriptions of antibody levels targeting the receptor binding domain of the spike protein of SARS-CoV-2 following administration of a primary BNT162b2 vaccine series.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Humoral immunity trends in a hemodialysis cohort following SARS‐CoV‐2 mRNA booster: A cohort study

Goggins,

Sharma,

et al. 2024

Health Science Reports

Self Cite

View full text Add to dashboard Cite

Background and AimsPatients with end stage kidney disease on hemodialysis are vulnerable to SARS‐CoV‐2 infection. Current guidelines recommend boosters of SARS‐CoV‐2 mRNA‐based vaccines. The long‐term humoral response of hemodialysis patients infected with SARS‐CoV‐2 after receiving a booster of SARS‐CoV‐2 mRNA‐based vaccines has been incompletely characterized. Here, we determined the long‐term humoral response of hemodialysis patients to two and three doses of the Pfizer BioNTech (BNT162b2) mRNA SARS‐CoV‐2 vaccine and investigated the effect of postbooster SARS‐CoV‐2 infection on antibody levels over time.MethodsSamples were collected on a monthly basis and tested for anti‐SARS‐CoV‐2 antibodies against anti‐spike S1 domain. Thirty‐five hemodialysis patients were enrolled in the original study and 27 of these received a booster. Patients were followed up to 6 months after the first two doses and an additional 7 months after the third BNT162b2 dose. Results are presented as the internationally harmonized binding antibody units (BAU/mL).ResultsAntibody level significantly increased from prebooster to 2 weeks postbooster, with a median [25th, 75th percentile] rise from 52.72 [28.55, 184.7] to 6216 [3806, 11,730] BAU/mL in the total population. Of patients with a negative or borderline detectable antibody level 6 months after vaccination who received a third dose, 89% developed positive antibody levels 2 weeks postbooster. Postbooster antibody levels declined an average rate of 29% per month in infection‐naïve patients. Antibody levels spiked in patients infected with SARS‐CoV‐2 after receiving a booster but declined rapidly. No patients infected postbooster required hospitalization.ConclusionsA third dose of BNT162b2 restores antibody levels to high levels in dialysis patients but levels decline over time. A third dose did not necessarily prevent infection, but no patients suffered severe infection or required hospitalization. SARS‐CoV‐2 recovered patients appear to have a blunted rise in antibody levels after a third dose. Although patients infected with SARS‐CoV‐2 postbooster had an immediate spike in antibody levels, these declined over time.

show abstract

Section: Goldblatt Et Al Reported the Mean Protective Threshold Again...mentioning

confidence: 73%

mentioning

confidence: 99%

SARS‐CoV‐2 booster effect and waning immunity in hemodialysis patients: A cohort study

Cited by 1 publication

References 13 publications

Humoral immunity trends in a hemodialysis cohort following SARS‐CoV‐2 mRNA booster: A cohort study

Humoral immunity trends in a hemodialysis cohort following SARS‐CoV‐2 mRNA booster: A cohort study

Contact Info

Product

Resources

About